What's in Ocuphire Pharma, Inc.'s pipeline?

Ocuphire Pharma, Inc. has 5 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Ocuphire Pharma, Inc.'s portfolio?

Top competitors by shared drug class: Allergan, LENZ Therapeutics, Inc, Maastricht University Medical Center, Nuvation Bio Inc., Taiho Oncology, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ocuphire-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ocuphire Pharma, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocuphire Pharma, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Phentolamine Ophthalmic Solution 0.75%	Phentolamine Ophthalmic Solution 0.75%	phase 3	Alpha-adrenergic antagonist	Alpha-1 and alpha-2 adrenergic receptors	Ophthalmology
Phentolamine Opthalmic Solution 0.75%	Phentolamine Opthalmic Solution 0.75%	phase 3	Alpha-adrenergic antagonist	Alpha-1 adrenergic receptor, Alpha-2 adrenergic receptor	Ophthalmology
Low dose pilocarpine	Low dose pilocarpine	phase 3	Muscarinic receptor agonist	Muscarinic acetylcholine receptors (M3, M4)	Ophthalmology

Therapeutic area mix

Ophthalmology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 1 shared drug class
LENZ Therapeutics, Inc · 1 shared drug class
Maastricht University Medical Center · 1 shared drug class
Nuvation Bio Inc. · 1 shared drug class
Taiho Oncology, Inc. · 1 shared drug class
sara nabil · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ocuphire Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Ocuphire Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ocuphire-pharma-inc. Accessed 2026-05-16.